img

Global IBS Treatment Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global IBS Treatment Market Research Report 2024

Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves.
According to Mr Accuracy reports’s new survey, global IBS Treatment market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole IBS Treatment market research.
Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global IBS Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Allergan (Ireland)
Sucampo Pharmaceuticals (U.S.)
Ironwood Pharmaceuticals (U.S.)
Astellas Pharma (Japan)
Bausch Health
Abbott Laboratories (U.S.)
Synergy Pharmaceuticals (U.S.)
Ardelyx (U.S.)
Nestle (Switzerland)
Sebela Pharmaceuticals (Ireland)
Probi (Sweden)
Alfasigma USA (Italy)
RedHill Biopharma (Israel)
AstraZeneca (U.K)
Ipsen (France)
Novartis (Switzerland)
Takeda Pharmaceutical Company (Japan)
Synthetic Biologics (U.S.)
Protagonist Therapeutics (U.S.)
Pfizer (U.S.)
Lexicon Pharmaceuticals (U.S.)
Innovate Biopharmaceuticals (U.S.)
Segment by Type
IBS-D
IBS-C
IBS-M

Segment by Application


Hospitals
Clinics
Research Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The IBS Treatment report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global IBS Treatment Market Size Growth Rate by Type: 2024 VS 2022 VS 2034
1.2.2 IBS-D
1.2.3 IBS-C
1.2.4 IBS-M
1.3 Market by Application
1.3.1 Global IBS Treatment Market Growth by Application: 2024 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Research Laboratories
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global IBS Treatment Market Perspective (2024-2034)
2.2 IBS Treatment Growth Trends by Region
2.2.1 Global IBS Treatment Market Size by Region: 2024 VS 2022 VS 2034
2.2.2 IBS Treatment Historic Market Size by Region (2024-2024)
2.2.3 IBS Treatment Forecasted Market Size by Region (2024-2034)
2.3 IBS Treatment Market Dynamics
2.3.1 IBS Treatment Industry Trends
2.3.2 IBS Treatment Market Drivers
2.3.3 IBS Treatment Market Challenges
2.3.4 IBS Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top IBS Treatment Players by Revenue
3.1.1 Global Top IBS Treatment Players by Revenue (2024-2024)
3.1.2 Global IBS Treatment Revenue Market Share by Players (2024-2024)
3.2 Global IBS Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by IBS Treatment Revenue
3.4 Global IBS Treatment Market Concentration Ratio
3.4.1 Global IBS Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by IBS Treatment Revenue in 2022
3.5 IBS Treatment Key Players Head office and Area Served
3.6 Key Players IBS Treatment Product Solution and Service
3.7 Date of Enter into IBS Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 IBS Treatment Breakdown Data by Type
4.1 Global IBS Treatment Historic Market Size by Type (2024-2024)
4.2 Global IBS Treatment Forecasted Market Size by Type (2024-2034)
5 IBS Treatment Breakdown Data by Application
5.1 Global IBS Treatment Historic Market Size by Application (2024-2024)
5.2 Global IBS Treatment Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America IBS Treatment Market Size (2024-2034)
6.2 North America IBS Treatment Market Growth Rate by Country: 2024 VS 2022 VS 2034
6.3 North America IBS Treatment Market Size by Country (2024-2024)
6.4 North America IBS Treatment Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe IBS Treatment Market Size (2024-2034)
7.2 Europe IBS Treatment Market Growth Rate by Country: 2024 VS 2022 VS 2034
7.3 Europe IBS Treatment Market Size by Country (2024-2024)
7.4 Europe IBS Treatment Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific IBS Treatment Market Size (2024-2034)
8.2 Asia-Pacific IBS Treatment Market Growth Rate by Region: 2024 VS 2022 VS 2034
8.3 Asia-Pacific IBS Treatment Market Size by Region (2024-2024)
8.4 Asia-Pacific IBS Treatment Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America IBS Treatment Market Size (2024-2034)
9.2 Latin America IBS Treatment Market Growth Rate by Country: 2024 VS 2022 VS 2034
9.3 Latin America IBS Treatment Market Size by Country (2024-2024)
9.4 Latin America IBS Treatment Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa IBS Treatment Market Size (2024-2034)
10.2 Middle East & Africa IBS Treatment Market Growth Rate by Country: 2024 VS 2022 VS 2034
10.3 Middle East & Africa IBS Treatment Market Size by Country (2024-2024)
10.4 Middle East & Africa IBS Treatment Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Allergan (Ireland)
11.1.1 Allergan (Ireland) Company Detail
11.1.2 Allergan (Ireland) Business Overview
11.1.3 Allergan (Ireland) IBS Treatment Introduction
11.1.4 Allergan (Ireland) Revenue in IBS Treatment Business (2024-2024)
11.1.5 Allergan (Ireland) Recent Development
11.2 Sucampo Pharmaceuticals (U.S.)
11.2.1 Sucampo Pharmaceuticals (U.S.) Company Detail
11.2.2 Sucampo Pharmaceuticals (U.S.) Business Overview
11.2.3 Sucampo Pharmaceuticals (U.S.) IBS Treatment Introduction
11.2.4 Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2024-2024)
11.2.5 Sucampo Pharmaceuticals (U.S.) Recent Development
11.3 Ironwood Pharmaceuticals (U.S.)
11.3.1 Ironwood Pharmaceuticals (U.S.) Company Detail
11.3.2 Ironwood Pharmaceuticals (U.S.) Business Overview
11.3.3 Ironwood Pharmaceuticals (U.S.) IBS Treatment Introduction
11.3.4 Ironwood Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2024-2024)
11.3.5 Ironwood Pharmaceuticals (U.S.) Recent Development
11.4 Astellas Pharma (Japan)
11.4.1 Astellas Pharma (Japan) Company Detail
11.4.2 Astellas Pharma (Japan) Business Overview
11.4.3 Astellas Pharma (Japan) IBS Treatment Introduction
11.4.4 Astellas Pharma (Japan) Revenue in IBS Treatment Business (2024-2024)
11.4.5 Astellas Pharma (Japan) Recent Development
11.5 Bausch Health
11.5.1 Bausch Health Company Detail
11.5.2 Bausch Health Business Overview
11.5.3 Bausch Health IBS Treatment Introduction
11.5.4 Bausch Health Revenue in IBS Treatment Business (2024-2024)
11.5.5 Bausch Health Recent Development
11.6 Abbott Laboratories (U.S.)
11.6.1 Abbott Laboratories (U.S.) Company Detail
11.6.2 Abbott Laboratories (U.S.) Business Overview
11.6.3 Abbott Laboratories (U.S.) IBS Treatment Introduction
11.6.4 Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2024-2024)
11.6.5 Abbott Laboratories (U.S.) Recent Development
11.7 Synergy Pharmaceuticals (U.S.)
11.7.1 Synergy Pharmaceuticals (U.S.) Company Detail
11.7.2 Synergy Pharmaceuticals (U.S.) Business Overview
11.7.3 Synergy Pharmaceuticals (U.S.) IBS Treatment Introduction
11.7.4 Synergy Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2024-2024)
11.7.5 Synergy Pharmaceuticals (U.S.) Recent Development
11.8 Ardelyx (U.S.)
11.8.1 Ardelyx (U.S.) Company Detail
11.8.2 Ardelyx (U.S.) Business Overview
11.8.3 Ardelyx (U.S.) IBS Treatment Introduction
11.8.4 Ardelyx (U.S.) Revenue in IBS Treatment Business (2024-2024)
11.8.5 Ardelyx (U.S.) Recent Development
11.9 Nestle (Switzerland)
11.9.1 Nestle (Switzerland) Company Detail
11.9.2 Nestle (Switzerland) Business Overview
11.9.3 Nestle (Switzerland) IBS Treatment Introduction
11.9.4 Nestle (Switzerland) Revenue in IBS Treatment Business (2024-2024)
11.9.5 Nestle (Switzerland) Recent Development
11.10 Sebela Pharmaceuticals (Ireland)
11.10.1 Sebela Pharmaceuticals (Ireland) Company Detail
11.10.2 Sebela Pharmaceuticals (Ireland) Business Overview
11.10.3 Sebela Pharmaceuticals (Ireland) IBS Treatment Introduction
11.10.4 Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2024-2024)
11.10.5 Sebela Pharmaceuticals (Ireland) Recent Development
11.11 Probi (Sweden)
11.11.1 Probi (Sweden) Company Detail
11.11.2 Probi (Sweden) Business Overview
11.11.3 Probi (Sweden) IBS Treatment Introduction
11.11.4 Probi (Sweden) Revenue in IBS Treatment Business (2024-2024)
11.11.5 Probi (Sweden) Recent Development
11.12 Alfasigma USA (Italy)
11.12.1 Alfasigma USA (Italy) Company Detail
11.12.2 Alfasigma USA (Italy) Business Overview
11.12.3 Alfasigma USA (Italy) IBS Treatment Introduction
11.12.4 Alfasigma USA (Italy) Revenue in IBS Treatment Business (2024-2024)
11.12.5 Alfasigma USA (Italy) Recent Development
11.13 RedHill Biopharma (Israel)
11.13.1 RedHill Biopharma (Israel) Company Detail
11.13.2 RedHill Biopharma (Israel) Business Overview
11.13.3 RedHill Biopharma (Israel) IBS Treatment Introduction
11.13.4 RedHill Biopharma (Israel) Revenue in IBS Treatment Business (2024-2024)
11.13.5 RedHill Biopharma (Israel) Recent Development
11.14 AstraZeneca (U.K)
11.14.1 AstraZeneca (U.K) Company Detail
11.14.2 AstraZeneca (U.K) Business Overview
11.14.3 AstraZeneca (U.K) IBS Treatment Introduction
11.14.4 AstraZeneca (U.K) Revenue in IBS Treatment Business (2024-2024)
11.14.5 AstraZeneca (U.K) Recent Development
11.15 Ipsen (France)
11.15.1 Ipsen (France) Company Detail
11.15.2 Ipsen (France) Business Overview
11.15.3 Ipsen (France) IBS Treatment Introduction
11.15.4 Ipsen (France) Revenue in IBS Treatment Business (2024-2024)
11.15.5 Ipsen (France) Recent Development
11.16 Novartis (Switzerland)
11.16.1 Novartis (Switzerland) Company Detail
11.16.2 Novartis (Switzerland) Business Overview
11.16.3 Novartis (Switzerland) IBS Treatment Introduction
11.16.4 Novartis (Switzerland) Revenue in IBS Treatment Business (2024-2024)
11.16.5 Novartis (Switzerland) Recent Development
11.17 Takeda Pharmaceutical Company (Japan)
11.17.1 Takeda Pharmaceutical Company (Japan) Company Detail
11.17.2 Takeda Pharmaceutical Company (Japan) Business Overview
11.17.3 Takeda Pharmaceutical Company (Japan) IBS Treatment Introduction
11.17.4 Takeda Pharmaceutical Company (Japan) Revenue in IBS Treatment Business (2024-2024)
11.17.5 Takeda Pharmaceutical Company (Japan) Recent Development
11.18 Synthetic Biologics (U.S.)
11.18.1 Synthetic Biologics (U.S.) Company Detail
11.18.2 Synthetic Biologics (U.S.) Business Overview
11.18.3 Synthetic Biologics (U.S.) IBS Treatment Introduction
11.18.4 Synthetic Biologics (U.S.) Revenue in IBS Treatment Business (2024-2024)
11.18.5 Synthetic Biologics (U.S.) Recent Development
11.19 Protagonist Therapeutics (U.S.)
11.19.1 Protagonist Therapeutics (U.S.) Company Detail
11.19.2 Protagonist Therapeutics (U.S.) Business Overview
11.19.3 Protagonist Therapeutics (U.S.) IBS Treatment Introduction
11.19.4 Protagonist Therapeutics (U.S.) Revenue in IBS Treatment Business (2024-2024)
11.19.5 Protagonist Therapeutics (U.S.) Recent Development
11.20 Pfizer (U.S.)
11.20.1 Pfizer (U.S.) Company Detail
11.20.2 Pfizer (U.S.) Business Overview
11.20.3 Pfizer (U.S.) IBS Treatment Introduction
11.20.4 Pfizer (U.S.) Revenue in IBS Treatment Business (2024-2024)
11.20.5 Pfizer (U.S.) Recent Development
11.21 Lexicon Pharmaceuticals (U.S.)
11.21.1 Lexicon Pharmaceuticals (U.S.) Company Detail
11.21.2 Lexicon Pharmaceuticals (U.S.) Business Overview
11.21.3 Lexicon Pharmaceuticals (U.S.) IBS Treatment Introduction
11.21.4 Lexicon Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2024-2024)
11.21.5 Lexicon Pharmaceuticals (U.S.) Recent Development
11.22 Innovate Biopharmaceuticals (U.S.)
11.22.1 Innovate Biopharmaceuticals (U.S.) Company Detail
11.22.2 Innovate Biopharmaceuticals (U.S.) Business Overview
11.22.3 Innovate Biopharmaceuticals (U.S.) IBS Treatment Introduction
11.22.4 Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2024-2024)
11.22.5 Innovate Biopharmaceuticals (U.S.) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global IBS Treatment Market Size Growth Rate by Type (US$ Million): 2024 VS 2022 VS 2034
Table 2. Key Players of IBS-D
Table 3. Key Players of IBS-C
Table 4. Key Players of IBS-M
Table 5. Global IBS Treatment Market Size Growth by Application (US$ Million): 2024 VS 2022 VS 2034
Table 6. Global IBS Treatment Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 7. Global IBS Treatment Market Size by Region (2024-2024) & (US$ Million)
Table 8. Global IBS Treatment Market Share by Region (2024-2024)
Table 9. Global IBS Treatment Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 10. Global IBS Treatment Market Share by Region (2024-2034)
Table 11. IBS Treatment Market Trends
Table 12. IBS Treatment Market Drivers
Table 13. IBS Treatment Market Challenges
Table 14. IBS Treatment Market Restraints
Table 15. Global IBS Treatment Revenue by Players (2024-2024) & (US$ Million)
Table 16. Global IBS Treatment Market Share by Players (2024-2024)
Table 17. Global Top IBS Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IBS Treatment as of 2022)
Table 18. Ranking of Global Top IBS Treatment Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by IBS Treatment Revenue (CR5 and HHI) & (2024-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players IBS Treatment Product Solution and Service
Table 22. Date of Enter into IBS Treatment Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global IBS Treatment Market Size by Type (2024-2024) & (US$ Million)
Table 25. Global IBS Treatment Revenue Market Share by Type (2024-2024)
Table 26. Global IBS Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 27. Global IBS Treatment Revenue Market Share by Type (2024-2034)
Table 28. Global IBS Treatment Market Size by Application (2024-2024) & (US$ Million)
Table 29. Global IBS Treatment Revenue Market Share by Application (2024-2024)
Table 30. Global IBS Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 31. Global IBS Treatment Revenue Market Share by Application (2024-2034)
Table 32. North America IBS Treatment Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 33. North America IBS Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 34. North America IBS Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 35. Europe IBS Treatment Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 36. Europe IBS Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 37. Europe IBS Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 38. Asia-Pacific IBS Treatment Market Size Growth Rate by Region (US$ Million): 2024 VS 2022 VS 2034
Table 39. Asia-Pacific IBS Treatment Market Size by Region (2024-2024) & (US$ Million)
Table 40. Asia-Pacific IBS Treatment Market Size by Region (2024-2034) & (US$ Million)
Table 41. Latin America IBS Treatment Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 42. Latin America IBS Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 43. Latin America IBS Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 44. Middle East & Africa IBS Treatment Market Size Growth Rate by Country (US$ Million): 2024 VS 2022 VS 2034
Table 45. Middle East & Africa IBS Treatment Market Size by Country (2024-2024) & (US$ Million)
Table 46. Middle East & Africa IBS Treatment Market Size by Country (2024-2034) & (US$ Million)
Table 47. Allergan (Ireland) Company Detail
Table 48. Allergan (Ireland) Business Overview
Table 49. Allergan (Ireland) IBS Treatment Product
Table 50. Allergan (Ireland) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 51. Allergan (Ireland) Recent Development
Table 52. Sucampo Pharmaceuticals (U.S.) Company Detail
Table 53. Sucampo Pharmaceuticals (U.S.) Business Overview
Table 54. Sucampo Pharmaceuticals (U.S.) IBS Treatment Product
Table 55. Sucampo Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 56. Sucampo Pharmaceuticals (U.S.) Recent Development
Table 57. Ironwood Pharmaceuticals (U.S.) Company Detail
Table 58. Ironwood Pharmaceuticals (U.S.) Business Overview
Table 59. Ironwood Pharmaceuticals (U.S.) IBS Treatment Product
Table 60. Ironwood Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 61. Ironwood Pharmaceuticals (U.S.) Recent Development
Table 62. Astellas Pharma (Japan) Company Detail
Table 63. Astellas Pharma (Japan) Business Overview
Table 64. Astellas Pharma (Japan) IBS Treatment Product
Table 65. Astellas Pharma (Japan) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 66. Astellas Pharma (Japan) Recent Development
Table 67. Bausch Health Company Detail
Table 68. Bausch Health Business Overview
Table 69. Bausch Health IBS Treatment Product
Table 70. Bausch Health Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 71. Bausch Health Recent Development
Table 72. Abbott Laboratories (U.S.) Company Detail
Table 73. Abbott Laboratories (U.S.) Business Overview
Table 74. Abbott Laboratories (U.S.) IBS Treatment Product
Table 75. Abbott Laboratories (U.S.) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 76. Abbott Laboratories (U.S.) Recent Development
Table 77. Synergy Pharmaceuticals (U.S.) Company Detail
Table 78. Synergy Pharmaceuticals (U.S.) Business Overview
Table 79. Synergy Pharmaceuticals (U.S.) IBS Treatment Product
Table 80. Synergy Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 81. Synergy Pharmaceuticals (U.S.) Recent Development
Table 82. Ardelyx (U.S.) Company Detail
Table 83. Ardelyx (U.S.) Business Overview
Table 84. Ardelyx (U.S.) IBS Treatment Product
Table 85. Ardelyx (U.S.) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 86. Ardelyx (U.S.) Recent Development
Table 87. Nestle (Switzerland) Company Detail
Table 88. Nestle (Switzerland) Business Overview
Table 89. Nestle (Switzerland) IBS Treatment Product
Table 90. Nestle (Switzerland) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 91. Nestle (Switzerland) Recent Development
Table 92. Sebela Pharmaceuticals (Ireland) Company Detail
Table 93. Sebela Pharmaceuticals (Ireland) Business Overview
Table 94. Sebela Pharmaceuticals (Ireland) IBS Treatment Product
Table 95. Sebela Pharmaceuticals (Ireland) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 96. Sebela Pharmaceuticals (Ireland) Recent Development
Table 97. Probi (Sweden) Company Detail
Table 98. Probi (Sweden) Business Overview
Table 99. Probi (Sweden) IBS Treatment Product
Table 100. Probi (Sweden) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 101. Probi (Sweden) Recent Development
Table 102. Alfasigma USA (Italy) Company Detail
Table 103. Alfasigma USA (Italy) Business Overview
Table 104. Alfasigma USA (Italy) IBS Treatment Product
Table 105. Alfasigma USA (Italy) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 106. Alfasigma USA (Italy) Recent Development
Table 107. RedHill Biopharma (Israel) Company Detail
Table 108. RedHill Biopharma (Israel) Business Overview
Table 109. RedHill Biopharma (Israel) IBS Treatment Product
Table 110. RedHill Biopharma (Israel) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 111. RedHill Biopharma (Israel) Recent Development
Table 112. AstraZeneca (U.K) Company Detail
Table 113. AstraZeneca (U.K) Business Overview
Table 114. AstraZeneca (U.K) IBS Treatment Product
Table 115. AstraZeneca (U.K) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 116. AstraZeneca (U.K) Recent Development
Table 117. Ipsen (France) Company Detail
Table 118. Ipsen (France) Business Overview
Table 119. Ipsen (France) IBS Treatment Product
Table 120. Ipsen (France) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 121. Ipsen (France) Recent Development
Table 122. Novartis (Switzerland) Company Detail
Table 123. Novartis (Switzerland) Business Overview
Table 124. Novartis (Switzerland) IBS Treatment Product
Table 125. Novartis (Switzerland) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 126. Novartis (Switzerland) Recent Development
Table 127. Takeda Pharmaceutical Company (Japan) Company Detail
Table 128. Takeda Pharmaceutical Company (Japan) Business Overview
Table 129. Takeda Pharmaceutical Company (Japan) IBS Treatment Product
Table 130. Takeda Pharmaceutical Company (Japan) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 131. Takeda Pharmaceutical Company (Japan) Recent Development
Table 132. Synthetic Biologics (U.S.) Company Detail
Table 133. Synthetic Biologics (U.S.) Business Overview
Table 134. Synthetic Biologics (U.S.) IBS Treatment Product
Table 135. Synthetic Biologics (U.S.) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 136. Synthetic Biologics (U.S.) Recent Development
Table 137. Protagonist Therapeutics (U.S.) Company Detail
Table 138. Protagonist Therapeutics (U.S.) Business Overview
Table 139. Protagonist Therapeutics (U.S.) IBS Treatment Product
Table 140. Protagonist Therapeutics (U.S.) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 141. Protagonist Therapeutics (U.S.) Recent Development
Table 142. Pfizer (U.S.) Company Detail
Table 143. Pfizer (U.S.) Business Overview
Table 144. Pfizer (U.S.) IBS Treatment Product
Table 145. Pfizer (U.S.) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 146. Pfizer (U.S.) Recent Development
Table 147. Lexicon Pharmaceuticals (U.S.) Company Detail
Table 148. Lexicon Pharmaceuticals (U.S.) Business Overview
Table 149. Lexicon Pharmaceuticals (U.S.) IBS Treatment Product
Table 150. Lexicon Pharmaceuticals (U.S.) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 151. Lexicon Pharmaceuticals (U.S.) Recent Development
Table 152. Innovate Biopharmaceuticals (U.S.) Company Detail
Table 153. Innovate Biopharmaceuticals (U.S.) Business Overview
Table 154. Innovate Biopharmaceuticals (U.S.) IBS Treatment Product
Table 155. Innovate Biopharmaceuticals (U.S.) Revenue in IBS Treatment Business (2024-2024) & (US$ Million)
Table 156. Innovate Biopharmaceuticals (U.S.) Recent Development
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Global IBS Treatment Market Size Comparison by Type (2024-2034) & (US$ Million)
Figure 2. Global IBS Treatment Market Share by Type: 2022 VS 2034
Figure 3. IBS-D Features
Figure 4. IBS-C Features
Figure 5. IBS-M Features
Figure 6. Global IBS Treatment Market Size Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global IBS Treatment Market Share by Application: 2022 VS 2034
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Research Laboratories Case Studies
Figure 11. IBS Treatment Report Years Considered
Figure 12. Global IBS Treatment Market Size (US$ Million), Year-over-Year: 2024-2034
Figure 13. Global IBS Treatment Market Size, (US$ Million), 2024 VS 2022 VS 2034
Figure 14. Global IBS Treatment Market Share by Region: 2022 VS 2034
Figure 15. Global IBS Treatment Market Share by Players in 2022
Figure 16. Global Top IBS Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IBS Treatment as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by IBS Treatment Revenue in 2022
Figure 18. North America IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 19. North America IBS Treatment Market Share by Country (2024-2034)
Figure 20. United States IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 21. Canada IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 22. Europe IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 23. Europe IBS Treatment Market Share by Country (2024-2034)
Figure 24. Germany IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 25. France IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 26. U.K. IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 27. Italy IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 28. Russia IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 29. Nordic Countries IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 30. Asia-Pacific IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 31. Asia-Pacific IBS Treatment Market Share by Region (2024-2034)
Figure 32. China IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 33. Japan IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 34. South Korea IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 35. Southeast Asia IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 36. India IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 37. Australia IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 38. Latin America IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 39. Latin America IBS Treatment Market Share by Country (2024-2034)
Figure 40. Mexico IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 41. Brazil IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 42. Middle East & Africa IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 43. Middle East & Africa IBS Treatment Market Share by Country (2024-2034)
Figure 44. Turkey IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 45. Saudi Arabia IBS Treatment Market Size YoY Growth (2024-2034) & (US$ Million)
Figure 46. Allergan (Ireland) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 47. Sucampo Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 48. Ironwood Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 49. Astellas Pharma (Japan) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 50. Bausch Health Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 51. Abbott Laboratories (U.S.) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 52. Synergy Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 53. Ardelyx (U.S.) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 54. Nestle (Switzerland) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 55. Sebela Pharmaceuticals (Ireland) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 56. Probi (Sweden) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 57. Alfasigma USA (Italy) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 58. RedHill Biopharma (Israel) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 59. AstraZeneca (U.K) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 60. Ipsen (France) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 61. Novartis (Switzerland) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 62. Takeda Pharmaceutical Company (Japan) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 63. Synthetic Biologics (U.S.) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 64. Protagonist Therapeutics (U.S.) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 65. Pfizer (U.S.) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 66. Lexicon Pharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 67. Innovate Biopharmaceuticals (U.S.) Revenue Growth Rate in IBS Treatment Business (2024-2024)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries